The broad, long term objectives of this continuation grant are to define the natural history of the two major adult cholestatic liver diseases, primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), by means of statistical models and to apply this knowledge to assess treatment efficacy and to optimize the timing of therapeutic intervention. At present, liver transplantation is the only therapy clinically accepted as lifesaving for these diseases. Because of improved transplantation survival rates during the past six years, randomizing patients into a nontransplantation (supportive treatment) control group has been considered clinically inappropriate. When developed, these statistical models can provide a mathematical control group to assess the efficacy of liver transplantation. In addition, statistical models will be developed to define risk factors and to predict outcome of liver transplantation. Another of the potentially important applications of the natural history model and the transplantation outcome model will be to improve the selection and timing of liver transplantation. Through such modeling, analyses will be performed to investigate whether patients in the """"""""early-advanced stage"""""""" of liver disease should receive transplantation immediately or should delay receiving the procedure until the disease reaches the """"""""late-advanced stage."""""""" The effect of transplantation on a patient's functional status, employability, and economic situation will be evaluated in addition to survival outcome. This proposal combines the strengths of two major medical centers, the Mayo Clinic and the University of Pittsburgh. At Mayo, NIH supported treatment trials have provided a unique, comprehensive, and longitudinal database for PBC and PSC patients without liver transplantation. This data base supports a novel approach to natural history modeling, which will describe the dynamic progression of the disease course as well as model survival outcome. The liver transplantation program at the University of Pittsburgh providws the largest single institutional experience in liver transplantation in the world. The Pittsburgh data, together with data from the Mayo transplantation program, provides outstanding resources for the development of the transplantation outcome models. These resources, together with the extensive clinical and statistical expertise in survival modeling at Mayo Clinic will provide answers to the critical issues of selection/timing and efficacy of liver transplantation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK034238-06
Application #
3232581
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Project Start
1986-01-15
Project End
1992-11-30
Budget Start
1991-01-01
Budget End
1992-11-30
Support Year
6
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kwong, Allison; Kim, W Ray; Mannalithara, Ajitha et al. (2018) Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. Liver Transpl 24:735-743
Heo, Nae-Yun; Mannalithara, Ajitha; Kim, Donghee et al. (2018) Long-term Patient and Graft Survival of Kidney Transplant Recipients With Hepatitis C Virus Infection in the United States. Transplantation 102:454-460
Kwong, Allison J; Kim, W Ray; Flemming, Jennifer A (2018) De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era. Hepatology 68:1288-1297
Yang, Ju Dong; Mannalithara, Ajitha; Piscitello, Andrew J et al. (2018) Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 68:78-88
Kwong, Allison J; Goel, Aparna; Mannalithara, Ajitha et al. (2018) Improved posttransplant mortality after share 35 for liver transplantation. Hepatology 67:273-281
Allen, Alina M; Heimbach, Julie K; Larson, Joseph J et al. (2018) Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation. Transplantation 102:1710-1716
Flemming, Jennifer A; Kim, W Ray; Brosgart, Carol L et al. (2017) Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 65:804-812
Kim, Sang Gyune; Larson, Joseph J; Lee, Ji Sung et al. (2017) Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates. Liver Transpl 23:733-740
Allen, Alina M; Kim, W Ray; Larson, Joseph J et al. (2016) The Epidemiology of Liver Diseases Unique to Pregnancy in a US Community: A Population-Based Study. Clin Gastroenterol Hepatol 14:287-94.e1-2
Yang, Ju Dong; Mohamed, Hager Amed; Cvinar, Jessica L et al. (2016) Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis. Am J Gastroenterol 111:1573-1580

Showing the most recent 10 out of 95 publications